A Novel Peptidome Technology for the Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease by Selected Reaction Monitoring
Journal of Alzheimer's Disease · 2024
DOI: 10.3233/jad-230915 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2024. Verfasst von Yusuke Fukui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Kitaku, Okayama, Japan. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Biomarkers. Die Arbeit nennt 34 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
With the aging of populations worldwide, Alzheimer’s disease (AD) has become a concern due to its high prevalence and the continued lack of established treatments. Early diagnosis is required as a preventive intervention to modify the disease’s progression. In our previous study, we performed peptidomic analysis of serum samples obtained from AD patients and age-matched healthy subjects to seek peptide biomarker candidates for AD by using BLOTCHIP-MS analysis, and identified four peptides as AD biomarker candidates.
Objective
The objective was to validate the serum biomarker peptides to distinguish mild cognitive impairment (MCI) and AD in comparison to cognitively healthy controls using a new peptidome technology, the Dementia Risk Test.
Methods
We enrolled 195 subjects with normal cognitive function (NC; n = 70), MCI (n = 55), and AD (n = 70), The concentrations of cognitive impairment marker peptides (Fibrinogen α chain (FAC), Fibrinogen β chain (FBC), Plasma protease C1 inhibitor (PPC1I), α2-HS-glycoprotein (AHSG)) were quantified by using a selected reaction monitoring assay based on liquid chromatography-MS/MS.
Results
The present study confirmed that three peptides, FAC, FBC, and PPC1I, were significantly upregulated during the onset of AD. This three-peptide set was both highly sensitive in determining AD (sensitivity: 85.7%, specificity: 95.7%, AUC: 0.900) and useful in distinguishing MCI (sensitivity: 61.8%, specificity: 98.6%, AUC: 0.824) from NC.
Conclusions
In this validation study, we confirmed the high diagnostic potential of the three peptides identified in our previous study as candidate serum biomarkers for AD. The Dementia Risk Test may be a powerful tool for detecting AD-related pathological changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Kitaku, Okayama, Japan.
- Protosera, Inc., KENTO Innovation Park NK, Settsu, Osaka, Japan.
- Department of Neurology, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Zitieren
APA
Fukui, Y., Tadokoro, K., Hamada, M., Asada, K., Lee, L. J., Tachiki, H., Morihara, R., Abe, K., & Yamashita, T. (2024). A Novel Peptidome Technology for the Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease by Selected Reaction Monitoring. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-230915
Vancouver
Fukui Y, Tadokoro K, Hamada M, Asada K, Lee LJ, Tachiki H, et al. A Novel Peptidome Technology for the Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease by Selected Reaction Monitoring. Journal of Alzheimer's Disease. 2024. doi:10.3233/jad-230915
BibTeX
@article{Fukui2024,
author = {Fukui, Yusuke and Tadokoro, Koh and Hamada, Minaki and Asada, Kyoichi and Lee, Lyang-Ja and Tachiki, Hidehisa and Morihara, Ryuta and Abe, Koji and Yamashita, Toru},
title = {A Novel Peptidome Technology for the Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease by Selected Reaction Monitoring},
journal = {Journal of Alzheimer's Disease},
year = {2024},
doi = {10.3233/jad-230915}
}
EUVIMED